
AATB Learning
NAT Platform Changes
-
Register
- Non-member - $30
- Member - $15
Learning Objectives
- Summarize why the implementation of new testing platforms is essential to obtaining timely laboratory results.
- Distinguish between the Ultrio and Ultrio Elite assay.
- Explore NAT assay sensitivities for detecting HIV-1/2, HBV and HCV.
- Define potential emerging infectious diseases in which can be screened for using NAT technology.

Sara Dionne, PhD, D(ABHI)
Sara Dionne serves as VRL-Eurofins Vice President of Operations. She received her Ph.D. in the field of Microbiology & Immunology and started her career as Assistant Professor in the Department of Medicine at the University of Arizona. Dr. Dionne has worked in the field of laboratory testing for HCT/Ps for over a decade specializing in Infectious Disease and Microbiology screening of donors and biological products. She provides customized consultations for VRL-Eurofins clinical partners and is responsible for operational oversight of all VRL laboratories nationwide. Dr. Dionne is credentialed through the American Board of Histocompatibility and Immunogenetics and also serves as the Director of the Immunogenetics Department.

Jerry Holmberg, PhD, MS (CLS), MT (ASCP) SBB
Key:




